Minerva reported a GAAP net loss of USD 283.67 million for Q4 2025, compared with a GAAP net loss of USD 4.27 million a year earlier, driven mainly by a USD 321.5 million non-cash loss on issuance of convertible preferred stock and warrants. R&D expense in Q4 2025 rose 10% to USD 2.17 million, primarily due to higher consultant fees, while G&A expense increased 11% to USD 2.81 million, mainly due to higher compensation expenses partially offset by lower insurance costs. For FY 2025, Minerva posted a GAAP net loss of USD 293.42 million versus GAAP net income of USD 1.44 million in FY 2024, while non-GAAP adjusted net loss narrowed 17% to USD 15.99 million. Cash, cash equivalents and restricted cash totaled USD 82.4 million at Dec. 31, 2025, up nearly quadruple from a year earlier, following USD 80 million in gross proceeds from an October 2025 private placement. The company said initiation of its confirmatory Phase 3 trial of roluperidone in negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110700OMX_____CNEWS_EN_GNW9669429_en) on March 11, 2026, and is solely responsible for the information contained therein.
Comments